Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Novartis Pharmaceuticals has announced that the FDA has approved two single-pill combination medications, Diovan HCT and Exforge, as initial or 'first-line' therapies in patients likely to need multiple drugs to achieve their blood pressure goals.
Subscribe to our email newsletter
The FDA approval of Diovan HCT and Exforge for first-line use reinforces current US guideline recommendations to start appropriate patients on combination therapy. With the approvals, healthcare professionals are said to have have simplified treatment strategies to help control high blood pressure with Diovan HCT and Exforge.
The Diovan HCT and Exforge first-line approvals were based on several clinical trials in approximately 2,000 and 3,500 patients, respectively, in which both products demonstrated efficacy and tolerability in patients with mild-to-severe high blood pressure.
Trevor Mundel, head of global development functions at Novartis, said: “These approvals demonstrate our confidence in combination medications for this therapeutic category, while reinforcing the Novartis commitment to provide physicians with well-researched and effective treatments for high blood pressure.”